Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 2/20 | 0.62 |
| ▸ | HTT | P42858 | 3/20 | 0.51 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | HPGD | P15428 | 3/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.45 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.45 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.45 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.42 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL40401 | 0.88 | CHRM2 (0.69) | CHRM2HTTGAAALDH1A1HPGD | |
| Hydrochloric Acid SCHEMBL6065696 | 0.86 | CHRM2 (0.67) | CHRM2HTTGAAALDH1A1HPGD | |
| SCHEMBL4913105 | 0.84 | CHRM2 (0.77) | CHRM2HTTALDH1A1HPGDTSHR | |
| Diethylamine SCHEMBL8994091 | 0.84 | CHRM2 (0.48) | CHRM2HTTGAAALDH1A1HPGD | |
| SCHEMBL19244144 | 0.83 | GAA (0.46) | CHRM2HTTGAACYP2D6TSHR | |
| SCHEMBL13159608 | 0.83 | CHRM2 (0.69) | CHRM2HTTALDH1A1HPGDTSHR | |
| SCHEMBL4916612 | 0.82 | CHRM2 (0.81) | CHRM2HTTALDH1A1HPGDCYP2D6 | |
| SCHEMBL4912089 | 0.82 | CHRM2 (0.81) | CHRM2HTTALDH1A1HPGDCYP2D6 | |
| SCHEMBL5034679 | 0.82 | CHRM2 (0.81) | CHRM2HTTALDH1A1HPGDCYP2D6 | |
| SCHEMBL9457554 | 0.82 | CHRM2 (0.62) | CHRM2HTTGAAALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3004286-B1 | BROAD TEMPERATURE PERFORMANCE CHEMILUMINESCENT SYSTEMS AND METHODS | CYALUME TECH INC (US) | 2019-08-28 | — | — | EP | claimed |
| EP-1114021-B1 | NEW SALTS OF HMG-CoA REDUCTASE INHIBITORS | LEK TOVARNA FARMACEVTSKIH (SI) | 2004-07-14 | — | — | EP | claimed |
| US-20250136594-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2025-05-01 | — | — | US | disclosed |
| EP-4469438-A1 | COMPOUNDS AND METHODS OF USE | Tango Therapeutics, Inc. (US) | 2024-12-04 | — | — | EP | disclosed |
| WO-2023146987-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
| WO-2023146987-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
| US-20230219951-A1 | PYRIDINE-PYRIMIDINE DERIVATIVE, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) | 2023-07-13 | — | — | US | disclosed |
| US-20230062022-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | NUVATION BIO INC (US) | 2023-03-02 | — | — | US | disclosed |
| WO-2022267930-A1 | TRICYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | 中国医药研究开发中心有限公司 | 2022-12-29 | — | — | WO | disclosed |
| WO-2021101919-A1 | COMPOUNDS USEFUL AS INHIBITORS OF HELIOS PROTEIN | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-05-27 | — | — | WO | disclosed |
| US-20210130473-A1 | TGFßR1 INHIBITOR-ASGR ANTIBODY CONJUGATES AND USES THEREOF | SILVERBACK THERAPEUTICS, INC. | 2021-05-06 | — | — | US | disclosed |
| US-7528140-B2 | Substituted pyrrolo[3,2-d]pyrimidines as glycogen synthase kinase (GSK) inhibitors | TEIJIN LIMITED (JP) | 2009-05-05 | — | — | US | disclosed |
| US-7528140-B2 | Substituted pyrrolo[3,2-d]pyrimidines as glycogen synthase kinase (GSK) inhibitors | TEIJIN LIMITED (JP) | 2009-05-05 | — | — | US | disclosed |
| US-7504391-B2 | Selective D1/D5 receptor antagonists for the treatment of obesity and CNS disorders | SCHERING CORPORATION (US) | 2009-03-17 | — | — | US | disclosed |
| US-7482359-B2 | Androgen receptor modulators | MERCK & CO., INC. (US) | 2009-01-27 | — | — | US | disclosed |
| US-20070269405-A1 | Androgen Receptor Modulators | MERCK SHARP & DOHME CORP. | 2007-11-22 | — | — | US | disclosed |
| WO-2006130552-A2 | METHODS OF TREATING HEPATITIS C VIRUS | SCHERING CORPORATION (US) | 2006-12-07 | — | — | WO | disclosed |
| WO-2006130554-A2 | METHODS OF TREATING HEPATITIS C VIRUS | SCHERING CORPORATION (US) | 2006-12-07 | — | — | WO | disclosed |
| EP-0382053-B1 | PROCESS FOR THE PREPARATION OF ANTHRAQUINONE DERIVATIVES | BASF Aktiengesellschaft (DE) | 1993-09-22 | — | — | EP | disclosed |
| EP-0382053-A2 | Process for the preparation of anthraquinone derivatives | BASF Aktiengesellschaft (DE) | 1990-08-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250136594-A1 | COMPOUNDS AND METHODS OF USE | CNKSR1, UGT1A1, REV1 | CHRM2 1738/4885HTT 1100/4885GAA 1665/4885 |
| US-20070269405-A1 | Androgen Receptor Modulators | AR, SHBG, FSHR | CHRM2 803/4885HTT 979/4885GAA 2442/4885 |
| US-20230062022-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | CDK4, CDK6, CDK8 | CHRM2 4882/4885HTT 1833/4885GAA 2341/4885 |
| US-20210130473-A1 | TGFßR1 INHIBITOR-ASGR ANTIBODY CONJUGATES AND USES THEREOF | TGFBR2, ASGR1, TGFBR1 | CHRM2 2988/4885HTT 4718/4885GAA 1198/4885 |
| US-20230219951-A1 | PYRIDINE-PYRIMIDINE DERIVATIVE, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | WEE1, SOS1, HINT1 | CHRM2 4696/4885HTT 4683/4885GAA 2849/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.